Walleye Capital’s Cymabay Therapeutics CBAY Stock Holding History

Walleye Capital’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-47,796	Closed	-$851K	–	5674
2023 Q3	$713K	Sell	47,796 -186,847	-80%	-$2.48M	﹤0.01%	2528
2023 Q2	$2.57M	Buy	+234,643	New	+$2.18M	0.01%	1165
2023 Q1	–	Sell	-488,894	Closed	-$3.07M	–	4495
2022 Q4	$3.07M	Buy	488,894 +268,903	+122%	+$1.02M	0.06%	404
2022 Q3	$770K	Buy	+219,991	New	+$790K	0.01%	1154
2020 Q3	–	Sell	-39,124	Closed	-$137K	–	1001
2020 Q2	$137K	Buy	+39,124	New	+$113K	0.03%	483

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Walleye Capital's CBAY Position: Q4 2023 in Review

Walleye Capital sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 47,796 shares — an estimated $851K sold.

Walleye Capital first reported a position in CBAY in Q2 2020 and held it in 5 quarters. The position peaked at $3.07M in Q4 2022. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

Walleye Capital reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
Walleye Capital sold 47,796 Cymabay Therapeutics shares in Q4 2023, an estimated $851K.
Walleye Capital first reported a position in Cymabay Therapeutics in Q2 2020 and held it in 5 quarters.
Walleye Capital's Cymabay Therapeutics position peaked at $3.07M in Q4 2022.
200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Walleye Capital's 13F filing for Q4 2023, filed 14 Feb 2024.